Literature DB >> 34612771

Persistent fatigue among long-term non-Hodgkin lymphoma survivors.

Matthew R LeBlanc1, Sheryl Zimmerman2,3,4, Thomas W LeBlanc5,6, Ashley Leak Bryant7, Kathryn E Hudson8, Sophia K Smith5,9.   

Abstract

This study describes the prevalence and persistence of fatigue among a cohort of long-term non-Hodgkin lymphoma (NHL) survivors. Mailed surveys assessed quality-of-life including fatigue (SF-36) at baseline and five years. Logistic regression was used to identify factors associated with prevalence of fatigue at baseline and persistence of fatigue across timepoints. More than one-quarter (27.7%) of the 555 NHL survivors reported clinically meaningful fatigue at baseline and 18.7% reported persistent fatigue at five years. One-third (34.4%) reported clinically meaningful worsening of fatigue over time. Independent associations with persistent fatigue included female gender, less education, past chemotherapy, increased comorbidities, and posttraumatic stress symptoms (P <.05). Our findings suggest that one in three NHL survivors experience clinically meaningful fatigue long after their diagnosis and initial treatment. Furthermore, we found that fatigue worsens or persists for many, highlighting the need for vigilance in assessing and treating fatigue in this population.

Entities:  

Keywords:  Non-Hodgkin lymphoma; fatigue; oncology; survivorship; symptoms

Mesh:

Year:  2021        PMID: 34612771      PMCID: PMC9049187          DOI: 10.1080/10428194.2021.1984450

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  32 in total

1.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

2.  The social determinants of health: why should we care?

Authors:  Adina Preda; Kristin Voigt
Journal:  Am J Bioeth       Date:  2015       Impact factor: 11.229

Review 3.  Cancer-related fatigue--mechanisms, risk factors, and treatments.

Authors:  Julienne E Bower
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

4.  The PTSD Checklist-Civilian Version: reliability, validity, and factor structure in a nonclinical sample.

Authors:  Daniel Conybeare; Evelyn Behar; Ari Solomon; Michelle G Newman; T D Borkovec
Journal:  J Clin Psychol       Date:  2012-04-19

5.  Persons injured in the 2011 terror attacks in Norway - Relationship between post-traumatic stress symptoms, emotional distress, fatigue, sleep, and pain outcomes, and medical and psychosocial factors.

Authors:  Marianne Løvstad; Grethe Månum; Kristin Wisløff-Aase; Gertrud Sofie Hafstad; Johan Ræder; Ingar Larsen; Johan Kvalvik Stanghelle; Anne-Kristine Schanke
Journal:  Disabil Rehabil       Date:  2019-04-24       Impact factor: 3.033

Review 6.  Post-traumatic stress disorder: theory and treatment update.

Authors:  Heather A Kirkpatrick; Grant M Heller
Journal:  Int J Psychiatry Med       Date:  2014       Impact factor: 1.210

7.  C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy.

Authors:  Maria M Pertl; David Hevey; Noreen T Boyle; Martina M Hughes; Sonya Collier; Anne-Marie O'Dwyer; Andrew Harkin; M John Kennedy; Thomas J Connor
Journal:  Brain Behav Immun       Date:  2013-08-06       Impact factor: 7.217

8.  Cancer-related fatigue: appraising evidence-based guidelines for screening, assessment and management.

Authors:  Elizabeth J M Pearson; Meg E Morris; Carol E McKinstry
Journal:  Support Care Cancer       Date:  2016-04-26       Impact factor: 3.603

9.  Neurophysiological relationship of neuromuscular fatigue and stress disorder in PTSD patients.

Authors:  Mostafa Sarabzadeh; Manijeh Soleimanifar; Masoumeh Helalizadeh
Journal:  J Bodyw Mov Ther       Date:  2020-08-09

10.  Multiple Imputation by Fully Conditional Specification for Dealing with Missing Data in a Large Epidemiologic Study.

Authors:  Yang Liu; Anindya De
Journal:  Int J Stat Med Res       Date:  2015-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.